All n=76 | BET1 n=19 | BET2 n=19 | BVS n=19 | PLA n=19 | |
---|---|---|---|---|---|
Male, n (%) | 63 (82.9) | 17 (89.5) | 16 (84.2) | 14 (73.7) | 16 (84.2) |
Age (years), mean (SD) | 39.7 (13.1) | 38.9 (12.6) | 37.2 (13.9) | 46.5 (14.1) | 36.3 (9.9) |
Symptom duration (years), mean (SD) | 8.5 (7.9) | 8.3 (7.8) | 7.2 (7.2) | 10.7 (9.0) | 7.9 (7.5) |
New EoE diagnosis, n (%) | 27 (35.5) | 7 (36.8) | 6 (31.6) | 6 (31.6) | 8 (42.1) |
Time since EoE diagnosis (years), mean (SD) | 2.2 (3.6) | 1.9 (3.4) | 1.8 (2.0) | 2.6 (3.3) | 2.6 (5.1) |
Concomitant treatment with PPI, n (%) | 10 (13.2) | 3 (15.8) | 1 (5.3) | 3 (15.8) | 3 (15.8) |
Concomitant allergic disease, n (%) | 49 (64.5) | 14 (73.7) | 14 (73.7) | 11 (57.9) | 10 (52.6) |
History of PPI, n (%) | 29 (38.2) | 9 (47.4) | 7 (36.8) | 6 (31.6) | 7 (36.8) |
History of topical steroids, n (%) | 20 (26.3) | 4 (21.1) | 2 (10.5) | 6 (31.6) | 8 (42.3) |
History of systemic steroids, n (%) | 5 (6.6) | 1 (5.3) | 1 (5.3) | 1 (5.3) | 2 (10.5) |
History of endoscopic dilatation, n (%) | 10 (13.2) | 2 (10.5) | 3 (15.8) | 4 (21.1) | 1 (5.3) |
BET1, effervescent tablets for orodispersible use 2×1 mg/day; BET2, effervescent tablets for orodispersible use 2×2 mg/day ; BVS, budesonide viscous suspension 2×5 mL (0.4 mg/mL)/day; EoE, eosinophilic oesophagitis; PLA, placebo; PPI, proton pump inhibitor.